Research programme: antifungals - Intercell AG

Drug Profile

Research programme: antifungals - Intercell AG

Latest Information Update: 09 Mar 2012

Price : $50

At a glance

  • Originator Intercell
  • Class Monoclonal antibodies; Vaccines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Aspergillosis; Candidiasis

Most Recent Events

  • 21 Apr 2011 Discontinued - Preclinical for Aspergillosis in Austria (unspecified route)
  • 21 Apr 2011 Discontinued - Preclinical for Candidiasis in Austria (unspecified route)
  • 21 Apr 2008 Preclinical trials in Aspergillosis in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top